BioNTech SE
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0A3M.IL | ROIV | 1877.HK | GMAB | IOVA | IBRX | |
|---|---|---|---|---|---|---|
| Market cap | 24.98B | 25.22B | 17.65B | 24.02B | 6.73B | 9.29B |
| P/E (TTM) | 5.0 | — | — | 30.8 | — | — |
| Forward P/E | 5.0 | -20.3 | 86.2 | 25.8 | -75.9 | -54.8 |
| Price/book | 1.1 | 6.0 | 2.5 | 3.9 | 9.1 | -8.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −16.59% | +94.43% | −37.10% | +30.58% | +591.16% | +245.08% |
| Today | +1.47% | +0.63% | +3.74% | +1.48% | +4.57% | +4.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 0A3M.IL news ›Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
The Motley Fool The personalized cancer vaccine landscape is arguably at an inflection point. Moderna (MRNA -7.82%), one of the leaders in the space, posted outstanding Phase 3 clinical trial results for one of its candidates, intismeran…
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 Red Cat…
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't ahead of a critical trial readout later this month. Profit taking is hitting one of biotech’s…
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)
BioNTech (NASDAQ:BNTX – Get Free Report) and MiMedx Group (NASDAQ:MDXG – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends,…
BioNTech (NASDAQ:BNTX) Stock Gets Price Target Reduction from Canaccord Genuity Group
Posted by Danessa Lincoln on Oct 17th, 2026 BioNTech (NASDAQ:BNTX – Free Report) had its price objective decreased by Canaccord Genuity Group from $136.00 to $132.00 in a research note published on Wednesday morning, Marketbeat Ratings…
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why. Two other healthcare stocks are rising alongside…
Engitix Appoints Former BioNTech Executive Ryan Richardson To Board Of Directors
Engitix has appointed Ryan Richardson as an Independent Non-Executive Director as the biotechnology company advances its proprietary pipeline toward clinical development and expands its platform and partnership strategy. Previously, he…
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
BioPharm International connects biopharmaceutical professionals with scientific and business insights on biopharma R&D, manufacturing & regulatory issues. BioNTech announced October 13, 2026, that the phase 2/3 AHEAD-MERIT trial did not…
BioNTech’s mRNA Cancer Vaccine Falls Short of Goal in Trial
A messenger ribonucleic acid (mRNA) vaccine against cancer failed to meet a primary goal of a late-stage clinical trial, the shot’s manufacturer said on Oct. 13. The experimental vaccine, known as BNT113, fell short of its primary endpoint…
BioNTech's Experimental Cancer Therapy Fails Key Trial Goal
Bengaluru: BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. US-listed shares of the drug developer were down nearly…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
247wallst.com5
-
stocktitan.net5
-
themarketsdaily.com5
-
defenseworld.net4
-
fool.com4
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 51 articles, not a forecast.